- Home
- LBTYK vs PBLS Comparison
LBTYK vs PBLS Comparison
Compare LBTYK & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | PBLS |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | LBTYK | PBLS |
|---|---|---|
| Price | $10.24 | $34.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 422.3K |
| Earning Date | 02-18-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $25.56 |
| 52 Week High | $13.12 | $36.82 |
Technical Indicators
Market Signals| Indicator | LBTYK | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 66.54 |
| Support Level | $9.30 | $26.42 |
| Resistance Level | $11.47 | N/A |
| Average True Range (ATR) | 0.36 | 2.61 |
| MACD | 0.09 | 0.40 |
| Stochastic Oscillator | 83.28 | 88.08 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About PBLS Parabilis Medicines Inc. Common Stock
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.